INTRODUCTION

Parkinson’s disease (PD) is the second most common neurodegenerative disease. Progressive supranuclear palsy (PSP) is the most commonly observed disease among Parkinson plus syndromes (1). From its onset, PSP cannot usually be accurately diagnosed, especially by inexperienced neurologists (2). The NINDS-SPSP criteria are used for the clinical diagnosis of PSP (3). Clinical characteristics include early onset postural instability, vertical gaze palsy, symmetrical parkinsonism with serious axial symptoms and non-responsive to L-dopa, pseudobulbar dysarthria, dysphagia, and frontal dysfunction. The majority of cases are sporadic (4). The incidence of PSP is 4%-6% among all parkinsonisms (5). PSP is a tauopathy disorder, and neuropathology is needed for its definite diagnosis. Neurofibrillary tangles are present in several subcortical areas such as the substantia nigra, subthalamic nucleus, and midbrain.

Data regarding the subtypes of PSP is increasing in the literature (6,7). According to the data present in the literature, there are eight different subtypes of PSP, namely Richardson’s syndrome (PSP-RS), PSP with predominant parkinsonism (PSP-P), PSP with pure akinesia with gait freezing (PSP-PAGF), PSP with corticobasal syndrome (PSP-CBS), PSP with predominant language and speech dysfunction (PSP-PNFA and PSP-AOS), PSP with predominant frontotemporal dysfunction (PSP-FTD), PSP with cerebellar ataxia (PSP-C), and PSP with primary lateral sclerosis (PSP-PLS) (8). The most significant challenge regarding the diagnosis of PSP-P arises owing to the phenotype. This is not usually possible to diagnose PSP type until the later stages of the disease due to lack of decisive biomarkers.

In a recent article published by the PSP Study Group of Movement Disorder Society, four clinical areas (ocular dysfunction, postural unbalance, akinesia, and cognitive function impairment) are recommended for the clinical differential diagnosis of PSP. In addition, three clinical features contribute to the diagnostic accuracy at different stages. Accordingly, specific combinations of these characteristics describe the diagnosis criteria with under three subtypes (probable PSP, possible PSP, and suggestive PSP). Imaging features (midbrain atrophy or hypometabolism and/or postsynaptic striatal dopaminergic degeneration) and clinical features are among the supporting characteristics (9). Thus, there is needed to optimize for the accurate, early, and specific diagnosis of PSP.

This study aimed to determine the phenotypic subtypes of PSP and reveal their accompanying characteristics.

Cite this article as: Gültekin M. Phenotypic Variants of Patients with Progressive Supranuclear Palsy. Arch Neuropsychiatry 2017; DOI: 10.5152/npa.2017.22771
Methods
Patients who were diagnosed as having PSP at Erciyes University School of Medicine between June 2014 and December 2016 were included in this study. The approval of the local ethics committee and the consent of the patients were obtained.

Medical records of the patients who were followed up owing to the diagnosis of PSP were retrospectively assessed, and the latest clinical characteristics were noted. The NINDS-SPSP criteria were considered for the diagnosis of PSP (3). Clinical characteristics included the onset of disease at an age of ≥50 years, slower vertical eye movements or vertical gaze palsy, significant postural instability or falls during the first year, and accompanying symmetrical parkinsonism. In addition, cranial magnetic resonance (MR) images of all patients were examined. Conventional 1.5-Tesla MR imaging (MRI) sections were collected. The patients with evident rostral midbrain atrophy and hummingbird sign on MRI were included in this study (10). The criterion for the midbrain-to-pons ratio was <0.124 mm² (11). Patients with PSP who met the abovementioned characteristics were included in the study.

Each patient was extensively examined by a neurologist who had experience with movement disorders. Initial symptoms of the patients, their initial diagnosis, treatment responses, course of the disease with time, additional symptoms, cranial images, disabling symptoms, and predominant clinical characteristics were assessed according to the subtypes of PSP.

Statistics Analysis
Demographical and clinical data of the participants that were obtained within the scope of the study were evaluated using descriptive statistics. Mean±SD and median 25 and 75 percentile values are presented. Results of frequency analysis applied to certain data are given in Table 1, 2. The Statistical Package for the Social Sciences 15.0 (SPSS Inc.; Chicago, IL, USA) was used for analysis.

Results
We included 18 patients with PSP in this study. The mean age of the patients was 65.83 years. The mean age at onset was 61.78 (51–70) years. Furthermore, the mean disease duration was 4.06 (3–8) years. According to the NINDS-SPSP criteria, all patients were diagnosed as having probable PSP. All patients had postural instability that was characterized by falls within the first year. Subsequently, in the next years, they developed supranuclear gaze palsy and slowness in vertical saccades.

Considering the clinical characteristics of the 18 patients with PSP, only two patients were accurately diagnosed as having PSP diagnosis on the basis of the onset characteristics. Thirteen patients were followed up owing to a diagnosis of PD, and the remaining three patients were followed up for a diagnosis of ataxia. Most of the patients did not have tremors and cervical dystonia. However, most patients had eye opening apraxia and eyelid dystonia. The majority of patients (14/18) were non-responsive to L-dopa, and postural instability was a major problem. The patients were not followed up at the same center and by the same doctor regularly from the onset of the disease until admission to our polyclinic. Three patients were followed up for a diagnosis of ataxia. Clinicians might have diagnosed the patients as having ataxia owing to postural instability and frequent falls. Despite this, no cerebellar atrophy was observed on the MR images of the patients. The clinical characteristics of the patients are given in Table 1.

An evaluation of patients with PSP with respect to subtypes showed that five different subtypes were predominant characteristics. It is necessary to underline the fact that all patients had symmetrical parkinsonism, postural instability, and other clinical PSP characteristics together with predominant characteristics. However, the predominant subtypes were determined according to the major presentation during clinical examination and the course of the disease. PSP-RS was found to be the most common subtype. Atrophy of the midbrain with the preservation of the pons constitutes a specific pattern that resembles a hummingbird or penguin and is known as the hummingbird sign, which is sometimes also called the penguin silhouette sign, as observed on midsagittal sections. The hummingbird sign has a very high specificity (100%; sensitivity, 97.8%). Cranial MRI of a...
Accurately diagnosing PSP on the basis of its heterogeneous clinical course and predominant characteristics was difficult. Dugger et al. (12) assessed 64 patients who were diagnosed as having pathologically proven PSP and found that 36% of the patients had concomitant Alzheimer’s dementia, 20% had PD, 1% had Lewy body dementia, 44% had argyrophilic grains, 52% had cerebral white matter rarefaction, and 25% had cerebral amyloid angiography. As can be observed in this study, the clinical presentation of PSP greatly differs. O’Sullivan et al. (13) examined 110 patients who were pathologically confirmed to have PSP. The authors also showed that frequent falls occurred 3.9 (±2.5) years from the onset of the disorder. Also, they showed 4.2 (±2.9) years for cognitive deterioration, 6 (±2.5) years for speech defects to incomprehensibility, 6.4 (±2.4) years for dysphagia, and 6.4 (±2.7) for being wheelchair-bound.

Owing to the increasing number of studies in the literature, predominant characteristics of the subtypes of PSP are more clearly revealed (1). Akinetic rigid symptoms that are resistant to levodopa treatment are seen in PSP-RS. Axial muscles are affected and it lead to the tendency to fall back. Also, vertical gaze palsy is observed in the initial phase of the PSP-RS. Apathy, pseudobulbar speech, aphasia, and deteriorations in executive functions are also observed (14). PSP-P is presented by parkinsonism with asymmetrical onset. Distinguishing PSP-P from PD until the onset of vertical gaze disorder is difficult (15). PSP-PAGF is characterized by sudden and temporary freezings that are observed without tremor and rigidity; this can be deemed typical for an underlying PSP neuropathology (16). Sometimes, the onset of the disease may be dominated by clinical symptoms that are suitable for the behavioral and language variants as in PSP-FTD or PSP-PNFA (17,18). The underlying pathologies of PSP-CBS are diverse, and 70% of patients present tauopathy. PSP-CBS accounts for only 4% of all cases with PSP (19,20). PSP-C is more commonly observed in Japan, and patients have neural loss in cerebellar dentate nucleus and gliosis (21). PSP-PLS is a progressive disorder that is accompanied by spastic gait with the degeneration of upper neuron motors and bulbar weakness. There may also be deterioration in vertical saccades; however, there is limited data regarding the same (22).

Among the subtypes of PSP, PSP-RS (40%) is the most common (23). PSP-RS was also the most common subtype in our patient group (71/18), and it was followed by PSP-P (20%), PSP-FTD (15%), PSP-CBS (10%), PSP-AOS (5%), and PSP-PAGF (<5%) (6,14,24,25,26). In contrast, other subtypes of PSP are very rare (18,27,28). Although some studies suggest that the commonly used NINDS-SPSP criteria are very sensitive for PSP-RS, they are not very appropriate for detecting other clinical subtypes of PSP (23). Moreover, the existence of two or more PSP variants may seen in a single case. The specificity of clinical syndromes depending on the underlying pathology cause contradictions for diagnosis. Thus, the determination of dominant clinical features and symptoms, which are specific and sensitive to an underlying PSP pathology, is significant to increase the clinical diagnostic precision in atypical phenotypes of PSP.

Our study has some limitations such as a relatively low number of patients, retrospective design, and lack of neuropathological examination of patients with PSP.

**CONCLUSION**

Conducting future clinicopathological studies with large samples and multiple centers on PSP subtypes will help better understand the etiology of PSP and its specific neurodegenerative mechanisms. Classifying PSP with respect to its phenotypes may be useful for informing clinicians about the diverse clinical presentations of PSP, thereby possibly improving the diagnostic sensitivity of the disease.
REFERENCES


2. Lang AE. Clinical heterogeneity in progressive supranuclear palsy: challenges to diagnosis, pathogenesis and future therapies. Mov Disord 2014; 29:1707-1709. [CrossRef]


